In its latest set of recommendations, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PARC) reported “Acute generalized exanthematous pustulosis (AGEP) has been reported with use of ibuprofen-containing products. Now Marketing Authorization Holders (MAHs) of these products in the European Union will have to update product information to include new warnings. HBW provides details about AGEP, recommendations by PARC and the specific responsibility of the MAHs in question.